Skip to main content
IPEXNasdaqinactive

Inflection Point Acquisition Corp. V

·New York, NY, United States·CEO: Mr. Michael Blitzer

IPEX evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for IPEX—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

1.2/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

$124.8M

Cash Runway

0.9 mo

Lead Asset

Next Catalyst

Financial data as of Mar 31, 2026.

Run Inflection Point Acquisition Corp. V through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Inflection Point Acquisition Corp. V facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

No clinical pipeline tracked — this score reflects financial & catalyst signals only.

Cash Runway0.3

0.9 months

Financial Health2.0

OCF -$215K · Net income $240K

Pipeline MaturityN/A

No tracked pipeline phase

Pipeline BreadthN/A

No tracked pipeline candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Runway

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

29

Total value held

$41.1M

Showing top 10 of 29 institutional holders of Inflection Point Acquisition Corp. V. Open the full 13F history after sign-in.

Short Interest

as of Apr 30, 2026
% of float
0.1%
Days to cover
0.3
Shares short
5,007
Daily short volume (Jun 18, 2026)
8.4%

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

IPEX short interest

Governance

Frequently asked questions

Who is the CEO of Inflection Point Acquisition Corp. V?

Mr. Michael Blitzer is the chief executive officer of Inflection Point Acquisition Corp. V (IPEX).

Where is Inflection Point Acquisition Corp. V headquartered?

Inflection Point Acquisition Corp. V (IPEX) is headquartered in New York, NY, United States.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.